Rupatadine
Sponsors
J. Uriach and Company, Charite University, Berlin, Germany, Sherief Abd-Elsalam, St. Paul's Sinus Centre, Noucor Health S.A.
Conditions
Allergic RhinitisAllergyCold Contact UrticariaHealthyHepatic ImpairmentHuman Experimentation (Human Volunteers)Renal ImpairmentRheumatoid Arthritis
Phase 1
Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers
CompletedNCT00199225
Start: 2005-02-28End: 2005-07-31Target: 160Updated: 2005-12-15
A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions
CompletedNCT05356143
Start: 2021-12-02End: 2023-01-05Updated: 2023-03-23
Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
RecruitingNCT06708520
Start: 2022-11-21End: 2025-07-31Target: 48Updated: 2025-05-28
Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants.
CompletedNCT06736340
Start: 2022-11-17End: 2025-04-09Updated: 2025-05-28
Phase 2
Phase 3
Phase 4
Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance
TerminatedNCT00162786
Start: 2005-05-31End: 2005-11-30Target: 20Updated: 2006-10-20
Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects
NCT00258141
Target: 30Updated: 2005-11-24
Allergic Rhinitis Combination Pharmacotherapy Efficacy Study
WithdrawnNCT04601324
Start: 2020-12-15End: 2021-07-01Updated: 2023-10-31